Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



This Biotech Is Looking for a Fourth-Quarter Comeback

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

"We believe that the fourth quarter may be our strongest quarter of the year," said John Johnson, Dendreon's (NASDAQOTH: DNDNQ  )  chairman, CEO, and president.

Where have we heard the fourth-quarter-comeback plan before? Oh yes, from Johnson's predecessor who issued 2011 revenue guidance of $350 million to $400 million, with half of that coming in the fourth quarter. The plan didn't go so well.

Sales of Provenge, Dendreon's prostate cancer treatment, fell from $81.6 million in the fourth quarter to $67.6 million in the first quarter of the year. The company had warned that there would be some headwinds in the first quarter, but investors weren't expecting such gale force winds.

The largest impact to sales came from competition from new prostate cancer drugs Johnson & Johnson's (NYSE: JNJ  ) Zytiga and Astellas Pharma and Medivation's (NASDAQ: MDVN  ) Xtandi. In December, Zytiga was approved for use in patients who haven't received chemotherapy, the same patients that Provenge is approved to treat. Xtandi is still only approved as a second-line treatment after chemotherapy, but is listed as an earlier treatment in the National Comprehensive Cancer Network Compendium, the oncologist's bible for off-label treatment that insurers often use to make coverage decisions.

Both drugs are taken orally, while Provenge has a complex process of taking immune cells from a patient, training them to attack the cancer, and then infusing them back into the patient. For smaller offices, it's much easier to hand patients a prescription than to arrange the Provenge process for three separate treatments. Johnson & Johnson and Astellas are also much larger and can therefore focus on those smaller treatment centers better than Dendreon.

In addition to drawing away patients, Zytiga and Xtandi are also siphoning off resources from foundations that offer co-pay assistance, making it harder for patients to get help paying for Provenge.

Management said it's hoping to grow Provenge sales year over year and guided for second-quarter sales in the mid-$70 million range. To hit that 2013 goal, it'll need to have sales of about $180 million in the second half of the year. That's not as bad as predicting that level of sales in a single quarter like it did in 2011, but it's still a pretty tall order.

Call me skeptical.

Craving more? Check out our full report on Dendreon
Our premium research report on Dendreon outlines reasons to buy and sell Denreon as well as the biotech's plan to regain its former glory. Claim your copy by clicking here now.

Read/Post Comments (1) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On May 09, 2013, at 10:49 PM, bhessel wrote:

    Mr. Johnson did mention a few additional factors that lend credence to the company’s admittedly optimistic guidance.

    First, while it is too early to have been reflected in the top line (because it takes a while to qualify a patient for Provenge), the direct-to-consumer TV ad campaign that the company launched in March has reportedly produced some very positive preliminary metrics. Secondly, March sales were better than January and February, and April was better than March, so the vector is good. Thirdly, there appears to be a growing consensus among experts that for men with asymptomatic metastatic castrate-resistant prostate cancer, Provenge is the best first line treatment (BEFORE chemo). And finally, while there was a big drop off in sales to smaller practices, the rate of sales to the large customer base remained steady and Dendreon continued to add new large customers.

    I wouldn’t say it is unreasonable to be skeptical at this point, but a saving throw here is is not an entirely outlandish possibility either.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2420806, ~/Articles/ArticleHandler.aspx, 9/29/2016 8:15:49 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 10 hours ago Sponsored by:
DOW 18,339.24 110.94 0.61%
S&P 500 2,171.37 11.44 0.53%
NASD 5,318.55 0.00 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
DNDNQ $0.00 Down +0.00 +0.00%
Dendreon Corp CAPS Rating: *
JNJ $119.39 Up +0.17 +0.14%
Johnson and Johnso… CAPS Rating: *****
MDVN $0.00 Down +0.00 +0.00%
Medivation CAPS Rating: ****